Correction to: Niraparib: A Review in First-Line Maintenance Therapy in Advanced Ovarian Cancer
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1776-260X
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Correction to: Niraparib: A Review in First-Line Maintenance Therapy in Advanced Ovarian Cancer ; day:10 ; month:11 ; year:2021 ; pages:1
Targeted oncology ; (10.11.2021), 1
- Creator
-
Lee, Arnold
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s11523-021-00854-x
- URN
-
urn:nbn:de:101:1-2022012208342417015726
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:34 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Lee, Arnold
- SpringerLink (Online service)
Other Objects (12)
Niraparib: A Review in First-Line Maintenance Therapy in Advanced Ovarian Cancer
First-Line Management of Advanced High-Grade Serous Ovarian Cancer
Efficacy and Safety of Niraparib as First-Line Maintenance Treatment for Patients with Advanced Ovarian Cancer: Real-World Data from a Multicenter Study in China
First-Line Immunotherapy in Advanced Non-Small-Cell Lung Cancer
Real-World Outcomes Following First-Line Treatment in Patients with Advanced Ovarian Cancer with Multiple Risk Factors for Disease Progression who Received Maintenance Therapy or Active Surveillance
Cost-Effectiveness Analysis of Olaparib in Combination with Bevacizumab Compared with Bevacizumab Monotherapy for the First-Line Maintenance Treatment of Homologous Recombination Deficiency-Positive Advanced Ovarian Cancer
Olaparib First-Line Maintenance Monotherapy in BRCA-Mutated Epithelial Ovarian Cancer: Descriptive Analysis of the First French Real-World Data Study
Advanced Adrenocortical Carcinoma – What to do when First-Line Therapy Fails?
Correction to: Cost-Effectiveness Analysis of Olaparib in Combination with Bevacizumab Compared with Bevacizumab Monotherapy for the First-Line Maintenance Treatment of Homologous Recombination Deficiency-Positive Advanced Ovarian Cancer
AIH Therapy: Beyond First-Line
Avelumab first-line maintenance plus best supportive care (BSC) vs BSC alone for advanced urothelial carcinoma: JAVELIN Bladder 100 Japanese subgroup analysis
Small-cell lung carcinoma with ovarian metastasis 4 years after the first-line treatment
Niraparib: A Review in First-Line Maintenance Therapy in Advanced Ovarian Cancer
First-Line Management of Advanced High-Grade Serous Ovarian Cancer
Efficacy and Safety of Niraparib as First-Line Maintenance Treatment for Patients with Advanced Ovarian Cancer: Real-World Data from a Multicenter Study in China
First-Line Immunotherapy in Advanced Non-Small-Cell Lung Cancer
Real-World Outcomes Following First-Line Treatment in Patients with Advanced Ovarian Cancer with Multiple Risk Factors for Disease Progression who Received Maintenance Therapy or Active Surveillance
Cost-Effectiveness Analysis of Olaparib in Combination with Bevacizumab Compared with Bevacizumab Monotherapy for the First-Line Maintenance Treatment of Homologous Recombination Deficiency-Positive Advanced Ovarian Cancer
Olaparib First-Line Maintenance Monotherapy in BRCA-Mutated Epithelial Ovarian Cancer: Descriptive Analysis of the First French Real-World Data Study
Advanced Adrenocortical Carcinoma – What to do when First-Line Therapy Fails?
Correction to: Cost-Effectiveness Analysis of Olaparib in Combination with Bevacizumab Compared with Bevacizumab Monotherapy for the First-Line Maintenance Treatment of Homologous Recombination Deficiency-Positive Advanced Ovarian Cancer
AIH Therapy: Beyond First-Line
Avelumab first-line maintenance plus best supportive care (BSC) vs BSC alone for advanced urothelial carcinoma: JAVELIN Bladder 100 Japanese subgroup analysis
Small-cell lung carcinoma with ovarian metastasis 4 years after the first-line treatment
Niraparib: A Review in First-Line Maintenance Therapy in Advanced Ovarian Cancer
First-Line Management of Advanced High-Grade Serous Ovarian Cancer
Efficacy and Safety of Niraparib as First-Line Maintenance Treatment for Patients with Advanced Ovarian Cancer: Real-World Data from a Multicenter Study in China
First-Line Immunotherapy in Advanced Non-Small-Cell Lung Cancer
Real-World Outcomes Following First-Line Treatment in Patients with Advanced Ovarian Cancer with Multiple Risk Factors for Disease Progression who Received Maintenance Therapy or Active Surveillance
Cost-Effectiveness Analysis of Olaparib in Combination with Bevacizumab Compared with Bevacizumab Monotherapy for the First-Line Maintenance Treatment of Homologous Recombination Deficiency-Positive Advanced Ovarian Cancer
Olaparib First-Line Maintenance Monotherapy in BRCA-Mutated Epithelial Ovarian Cancer: Descriptive Analysis of the First French Real-World Data Study
Advanced Adrenocortical Carcinoma – What to do when First-Line Therapy Fails?
Correction to: Cost-Effectiveness Analysis of Olaparib in Combination with Bevacizumab Compared with Bevacizumab Monotherapy for the First-Line Maintenance Treatment of Homologous Recombination Deficiency-Positive Advanced Ovarian Cancer
AIH Therapy: Beyond First-Line
Avelumab first-line maintenance plus best supportive care (BSC) vs BSC alone for advanced urothelial carcinoma: JAVELIN Bladder 100 Japanese subgroup analysis